GSK Plans Annual Savings of £1.9 Billion to Enable R&D Spend
Macro·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
GSK Plc plans annual savings of £1.9 billion ($2.5 billion) by 2029, as the drugmaker invests more in its pipeline to replace revenue from the looming patent expiry of an HIV medicine.
The savings initiative is aimed at bolstering research and development efforts, ensuring the company can sustain its operations and innovate despite the challenges posed by patent expirations.
GSK
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“GSK Plc plans annual savings of £1.9 billion ($2.5 billion) by 2029, as the drugmaker invests more in its pipeline to replace revenue from the looming patent expiry of an HIV medicine.”
Bloomberg — GSK Plans Annual Savings of £1.9 Billion to Enable R&D Spend